Cargando…
Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically significant [Grade Group (GG) ≥2] cancer, however, screening carries substantial risks, including frequent unn...
Autores principales: | Eyrich, Nicholas W., Morgan, Todd M., Tosoian, Jeffrey J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350244/ https://www.ncbi.nlm.nih.gov/pubmed/34430413 http://dx.doi.org/10.21037/tau-20-1151 |
Ejemplares similares
-
Preface to “Current and Future Topics on Prostate Cancer”
por: Konety, Badrinath R., et al.
Publicado: (2021) -
Epigenetics in prostate cancer: clinical implications
por: Conteduca, Vincenza, et al.
Publicado: (2021) -
Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021) -
Every urologist and oncologist should know about treating sexual and gender minority prostate cancer patients: translating research findings into clinical practice
por: Rosser, B. R. Simon, et al.
Publicado: (2021) -
Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
por: Tosoian, Jeffrey J., et al.
Publicado: (2021)